Clinical trials: Bronchitis
Graft Versus Host Disease
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
The purpose of this research study is to determine the safety of IL-2 and the highest dose of this drug that can be given safely to people with chronic graft versus host disease (GVHD).
- Trial name
- NCT00529035
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Graft Versus Host Disease
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
Chronic graft versus host diseasre (GVHD) is a serious reaction that might occur in a person (the host) who has received cells or organs (graft) from another person because the graft attacks the host's cells.
- Trial name
- NCT02461134
- Testing
- Ponesimod
- Volunteers
- 1 people
- Sponsor
- Actelion
Bronchiolitis
Nebulized 3% Hypertonic Saline vs. Standard of Care in Patients With Bronchiolitis
The purpose of this study is to determine whether nebulized 3% hypertonic saline is more effective than the current standard of care in the treatment of viral bronchiolitis in children.
- Trial name
- NCT02834819
- Testing
- 3% Nebulized Hypertonic Saline
- Volunteers
- 18 people
- Sponsor
- University of Colorado, Denver
Bronchiolitis Obliterans, Constructive Bronchiolitis
Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Bronchiolitis Obliterans (BO) is an obstructive lung disease that can affect individuals that have undergone a lung or hematopoietic stem cell transplant.
- Conditions
- Bronchiolitis Obliterans, Constructive Bronchiolitis, Graft Versus Host Disease, Bronchiolitis, Exudative
- Trial name
- NCT01273207
- Testing
- Cyclosporine Inhalation Solution (CIS)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myelodysplastic Syndromes
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment Reason…
- Trial name
- NCT02281084
- Testing
- Oral Azacitidine, Durvalumab
- Where
- 89 sites in United States, Australia and 8 more
- Volunteers
- 65 people
- Sponsor
- Celgene
Wheezy Bronchitis, Asthmatic Bronchitis
Efficacy of Intermittent Tiotropium in Early Childhood Wheezing
This study evaluates the effect of intermittent tiotropium bromide and salbutamol as needed versus intermittent fluticasone propionate and salbutamol as needed, or solely, salbutamol as needed on episode-free days in infants and…
- Conditions
- Wheezy Bronchitis, Asthmatic Bronchitis, Wheezing, Obstruction Airway
- Trial name
- NCT03199976
- Testing
- Tiotropium Bromide, Fluticasone Propionate, Salbutamol
- Where
- Finland
- Volunteers
- 80 people
- Sponsor
- Helsinki University Central Hospital
Chronic Graft Versus Host Disease
Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease
This phase II trial studies how well ixazomib citrate works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant, usually…
- Trial name
- NCT02513498
- Testing
- Ixazomib Citrate, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Graft-versus-host-disease
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
This study is being done in patients who have been receiving corticosteroids or other immunosuppressive therapies for the treatment of cGVHD for at least 6 months.
- Trial name
- NCT04200365
- Testing
- Itacitinib
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- SCRI Development Innovations, LLC
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in…
- Trial name
- NCT01572792
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate
- Where
- 208 sites in United States, Australia and 2 more
- Volunteers
- 921 people
- Sponsor
- AstraZeneca
Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901328
- Testing
- CB-5945
- Volunteers
- 49 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Effect of BIBW 2948 BS in COPD
Study of BIBW 2948 BS in Patients with COPD and Chronic Bronchitis
- Trial name
- NCT00423137
- Testing
- BIBW 2948 BS
- Where
- 6 sites in United States, Germany
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.
- Trial name
- NCT00950807
- Testing
- Tiotropium, GSK573179
- Where
- 19 sites in United States, Germany
- Volunteers
- 176 people
- Sponsor
- GlaxoSmithKline
Graft Vs Host Disease
Ibrutinib and Rituxan for Chronic GVHD
This is a phase II trial evaluating the safety and efficacy of the combination of Ibrutinib and Rituximab as primary treatment of chronic GVHD. We plan to enroll 35 patients on this study.
- Trial name
- NCT04235036
- Testing
- Rituximab, Ibrutinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northside Hospital, Inc.
Lower Respiratory Tract Infection (LRTI)
Procalcitonin Antibiotic Consensus Trial (ProACT)
The ProACT study is a 5 year, multicenter study that will test the effect of implementation of a novel procalcitonin guideline on antibiotic use and adverse outcomes in Emergency Department (ED) patients with Lower Respiratory…
- Trial name
- ProACT (NCT02130986)
- Testing
- Procalcitonin level, Results of procalcitonin (PCT) level to treating clinician, Provide procalcitonin guideline to treating clinician
- Where
- 13 sites in United States
- Volunteers
- 1,664 people
- Sponsor
- University of Pittsburgh
COPD, Chronic Bronchitis
Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
The purpose of this study is to show that one form of mechanical airway clearance techniques, High Frequency Chest Wall Oscillation (HFCWO)using a pneumatic vest, will diminish exacerbations of COPD which will improve respiratory…
- Conditions
- COPD, Chronic Bronchitis, Emphysema
- Trial name
- NCT00181207
- Testing
- pneumatic vest
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins University
Chronic Low Back Pain
Placebo In Chronic Back Pain (Phase 2)
This study is designed to examine brain properties for placebo response in chronic back pain patients. The investigators have preliminary data indicating that, in blinded clinical trial studies with neutral instructions regarding…
- Trial name
- PICP2 (NCT02986334)
- Testing
- Naproxen, Omeprazole
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Apkar Apkarian
Migraine, Headache
Ticagrelor Therapy for RefrACTORy Migraine Study
This is a prospective, open-label, single-arm pilot study treating 40 subjects to assess the hypothesis that P2Y, G protein-coupled 12 (P2Y12) inhibition with Brilinta/ticagrelor (90 mg by mouth (PO) twice a day) reduces episodic…
- Conditions
- Migraine, Headache, Migraine Headache
- Trial name
- TRACTOR (NCT02518464)
- Testing
- Ticagrelor 90 mg twice per day
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Hematological Malignancies
Rituximab for Prevention of Chronic GVHD
The purpose of this trial is to determine if administration of rituximab after allogeneic stem cell transplantation can reduce the incidence of chronic GVHD.
- Trial name
- NCT00379587
- Testing
- Rituximab, 375 mg/m2 RRituximab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Dana-Farber Cancer Institute
Anemia, Kidney Disease, Chronic
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis
This prospective observational study will evaluate the safety and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic renal anemia on haemodialysis in maintenance ESA treatment.
- Trial name
- NCT01422824
- Where
- 6 sites in North Macedonia
- Volunteers
- 185 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Lymphocytic
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
This study will evaluate the effectiveness of an experimental drug called LMB-2 for treating chronic lymphocytic leukemia (CLL) in patients who have a protein called cluster of differentiation 25 (CD25) on their cancer cells.
- Conditions
- Leukemia, Lymphocytic, Chronic
- Trial name
- NCT00077922
- Testing
- LMB-2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)